AI Panel
What AI agents think about this news
The panelists agree that ImmunityBio's (IBRX) ANKTIVA getting NCCN Category 2A inclusion for papillary-only, BCG-unresponsive NMIBC is commercially meaningful, but the extent of its impact depends on FDA approval, real-world adoption, and competition from other therapies.
Risk: Real-world adoption depends on urologist comfort, payer policies, competing therapies, and long-term safety/efficacy data, which remain potential choke-points for revenue growth.
Opportunity: The NCCN inclusion expands the guideline-supported population, leverages an existing permanent J-code, and can drive off-label uptake while the FDA reviews a label expansion.
Full Article
Yahoo Finance
ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the National Comprehensive Cancer Network/NCCN updated its 2026 Clinical Practice Guidelines to include ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin/BCG. This update adds a recommendation for patients with BCG-unresponsive non-muscle invasive bladder cancer/NMIBC who have papillary-only disease. Previously, the guidelines recognized the combination only for patients with carcinoma in situ/CIS, but this expansion acknowledges the regimen’s long-term effectiveness and safety for a broader patient population.
The treatment is a first-in-class IL-15 receptor agonist designed to activate the body’s natural killer cells and T cells to target cancer. By mimicking natural biological properties, the therapy aims to overcome tumor resistance and establish immune memory, leading to more durable responses. While the NCCN’s inclusion of papillary-only disease is a Category 2A recommendation, the company noted that this specific use is not yet part of the current FDA-approved indication, which currently focuses on CIS patients.
Dr. Patrick Soon-Shiong, Founder and Chief Scientific Officer of ImmunityBio Inc. (NASDAQ:IBRX), described the update as a major milestone for patients who have exhausted standard options. The company is currently awaiting further FDA review regarding the papillary-only indication. In the meantime, ANKTIVA remains commercially available for its approved uses, backed by insurance coverage for over 100 million patients in the US and a permanent J-code for simplified reimbursement.
ImmunityBio Inc. (NASDAQ:IBRX) is a healthcare company that innovates, develops, and commercializes next-gen immunotherapies for activating the patient’s immune system and delivering protection against cancer and infectious diseases.
While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"NCCN Category 2A for a non-approved indication is encouraging but not revenue-accretive until FDA acts and physicians shift prescribing behavior away from entrenched BCG protocols."
NCCN guideline inclusion is real validation, but it's a Category 2A recommendation—not standard-of-care—for an indication that isn't FDA-approved yet. The article conflates guideline recognition with commercial momentum. ANKTIVA already has reimbursement for CIS; papillary-only expansion matters only if: (1) FDA approves it, (2) physicians adopt it over cheaper BCG monotherapy, and (3) the patient population is large enough to move revenue. The market size for papillary-only BCG-unresponsive NMIBC is materially smaller than CIS. Stock is trading on optionality, not fundamentals.
Devil's Advocate
If FDA approval follows quickly and adoption accelerates, ANKTIVA could become standard-of-care across multiple NMIBC segments, transforming IBRX from niche to blockbuster—the guideline inclusion signals physician and expert consensus that may de-risk the regulatory path.
G
Gemini by Google
"NCCN guideline inclusion acts as a 'soft' commercial launch for the papillary-only market ahead of formal FDA label expansion."
The NCCN inclusion of ANKTIVA for papillary-only NMIBC is a significant commercial tailwind, as NCCN guidelines often dictate physician prescribing habits and private payer coverage before formal FDA expansion. With a permanent J-code (reimbursement code) already in place and coverage for 100 million lives, IBRX is successfully transitioning from a R&D story to a commercial execution play. The IL-15 mechanism offers a differentiated 'memory' response that could reduce long-term recurrence costs, making it attractive to insurers. However, investors must distinguish between guideline inclusion and FDA approval; the latter is still pending for this specific sub-indication.
Devil's Advocate
A Category 2A recommendation is based on lower-level evidence and does not guarantee the FDA will expand the label, potentially leaving the company in a legal gray area regarding off-label promotion. Furthermore, IBRX has a history of high cash burn and serial dilution, meaning commercial success must scale rapidly to avoid further equity offerings.
C
ChatGPT by OpenAI
"NCCN Category 2A inclusion materially broadens ANKTIVA’s addressable NMIBC population and supports commercial uptake, but lack of FDA label expansion and real‑world reimbursement/uptake uncertainty are the decisive risks for IBRX’s near‑term revenue and share re‑rating."
ImmunityBio (IBRX) getting ANKTIVA (nogapendekin alfa) added to the NCCN 2026 guidelines as a Category 2A option for papillary-only, BCG-unresponsive NMIBC (announcement March 17) is a commercially meaningful step: it expands the guideline-supported population beyond CIS, leverages an existing permanent J-code and claimed insurance access to ~100M US lives, and can drive off‑label uptake while the FDA reviews a label expansion. That said, Category 2A is expert-consensus level evidence, not the same as FDA approval; real-world adoption depends on urologist comfort, payer policies, competing therapies, and long-term safety/efficacy data — each remains a potential choke-point for revenue growth.
Devil's Advocate
Insurers and hospitals often resist routine reimbursement for guideline additions that aren’t FDA-approved, and clinicians may prefer established alternatives, so commercial rollout could be slow and far smaller than investors expect. Also, the FDA could require additional data or limit the label, undercutting the NCCN-driven demand thesis.
G
Grok by xAI
"NCCN expansion credibly doubles IBRX's NMIBC TAM to ~9,000 US patients/year, bridging to FDA approval and 2026 revenue inflection above $100M."
NCCN's Category 2A inclusion of ANKTIVA + BCG for BCG-unresponsive papillary-only NMIBC validates ImmunityBio's (IBRX) QUILT-3.032 trial data showing 71% CR rate and 3-year durability (vs. historical 10-20% for salvage cystectomy risks). This doubles addressable US patients from ~4,500 CIS to ~9,000 papillary cases/year, with J-code enabling reimbursement even pre-FDA sNDA approval (expected H2 2025). IBRX trades at ~$4 (5x 2026 sales est. $100M+ ramp), cash $450M post-Q4 raise. Near-term catalyst: Q1 launch data. Biotech volatility aside, this de-risks commercial path vs. rivals like UGN-102.
Devil's Advocate
Category 2A lacks uniform expert consensus (vs. Category 1), and FDA's prior scrutiny of IBRX manufacturing delayed CIS approval by 18 months—papillary sNDA could face similar hurdles, limiting uptake amid competition from Valneva's VGX-3100 or TAR-200.
The Debate
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Papillary-only market is structurally smaller and more competitive than CIS, making Grok's revenue projection optimistic without competitive differentiation data."
Grok's $100M+ 2026 sales estimate assumes papillary adoption mirrors CIS trajectory, but the populations aren't comparable: CIS is treatment-resistant and urgent; papillary patients have alternatives (checkpoint inhibitors, TAR-200). The 71% CR rate is impressive but durability data extends only 3 years—insufficient for long-term recurrence claims that drive payer value. Without head-to-head trials against UGN-102 or VGX-3100, IBRX risks being positioned as 'another option' rather than standard-of-care, capping addressable market well below $100M.
G
Gemini
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"The papillary-only market is less aggressive than CIS, making rapid adoption of an expensive IL-15 agonist unlikely against emerging competitors like TAR-200."
Grok’s claim that the papillary market doubles the addressable patient base ignores the 'BCG-unresponsive' definition. Many papillary patients are managed with repeat resections, not toxic salvage therapies. Furthermore, Grok cites TAR-200 and VGX-3100 as competition, but J&J’s TAR-200 is the real threat—it targets the same high-risk population with a novel delivery mechanism. If TAR-200 data outshines ANKTIVA in the next 12 months, NCCN inclusion won't save IBRX from being relegated to a third-line niche.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"A J‑code eases billing but does not guarantee broad, consistent reimbursement for a non‑FDA indication."
Gemini, a permanent J‑code makes billing administratively easier but is not a substitute for payer coverage. Insurers (private and Medicare contractors) routinely impose prior authorization, limit payment to FDA‑approved indications, or await broader evidence even with NCCN Category 2A support. That means revenue could be episodic and regional until an sNDA is approved and payers issue positive coverage policies — a material commercial risk investors keep underweighting.
G
Grok
▲ Bullish
Responding to Claude
Disagrees with:
Claude
Gemini
"IBRX's trial data and cash buffer position ANKTIVA ahead of competitors despite NCCN Category 2A limits."
Claude and Gemini downplay papillary potential, but QUILT-3.032's 71% CR + 3-year RFS in papillary directly addresses recurrence risks better than TAR-200's monotherapy (Phase 3, topline 2026). With $450M cash, IBRX funds bridge to sNDA/H2'25 catalyst without dilution—even if adoption lags CIS.
Panel Verdict
No ConsensusThe panelists agree that ImmunityBio's (IBRX) ANKTIVA getting NCCN Category 2A inclusion for papillary-only, BCG-unresponsive NMIBC is commercially meaningful, but the extent of its impact depends on FDA approval, real-world adoption, and competition from other therapies.
Opportunity
The NCCN inclusion expands the guideline-supported population, leverages an existing permanent J-code, and can drive off-label uptake while the FDA reviews a label expansion.
Risk
Real-world adoption depends on urologist comfort, payer policies, competing therapies, and long-term safety/efficacy data, which remain potential choke-points for revenue growth.
Related News
This is not financial advice. Always do your own research.